![]() ASM has published protocols for clinical laboratories to help them verify commercial SARS-CoV-2 kits. ![]() When we last checked (April 24th, 2020), there were 45 commercial COVID-19 test kits and 10 laboratory-developed tests (tests uniquely developed by the performing laboratory) that have received FDA EUA approval. The overall performance of SARS-CoV-2 RT-PCR tests cannot be known until we understand who is truly infected and who isn't. However, these analyses differ in meaning from clinical sensitivity and specificity (the percentage of positive patients who test positive and negative patients who test negative, respectively) and a test with good analytical sensitivity and specificity does not necessarily have good clinical sensitivity and specificity. Analytical sensitivity is the smallest amount of substance in a sample that can be reliably detected by an assay (limit of detection) and analytical specificity is the assay's ability to detect only the desired substance in a sample without cross reacting with other substances. ![]() The FDA's EUA templates require analytic sensitivity and specificity analyses. Clinical and commercial laboratories, as well as test kit manufacturers, may therefore submit expedited submissions for FDA EUAs of their diagnostic devices and assays. 4, 2020, the Human Health and Services (HHS) Secretary determined that there is a public health emergency, and therefore, circumstances justify the emergency use authorization (EUA) of in vitro diagnostics for the detection and/or diagnosis of SARS-CoV-2, the virus that causes COVID-19. Since the test is new, its performance needs to be compared to the performance of a current "gold-standard" test, also known as the "reference standard." There currently is no gold-standard diagnostic test for SARS-CoV-2 since the virus is new to us. In the cases where a new diagnostic panel is developed but can be used on existing equipment (the Centers for Disease Control and Prevention's SARS-CoV-2 assay, for example), a relatively lengthy FDA review may still be required under normal conditions (e.g. If the test is innovative, clinical studies are typically required to demonstrate adequate performance of the test. If a company wants to sell a new diagnostic testing platform, they normally have to endure a series of steps including test classification, applications and paying fees. Generally, lab tests are classified as in vitro diagnostics (IVD) by the Food and Drug Administration (FDA) and go through a rigorous approval process to gain FDA clearance. Caveat: evolving! What Tests Are Available for COVID-19 and How Are They 'Approved' in the U.S.? We break down some of the major challenges of SARS-CoV-2 testing, including issues of test performance and interpretation, to give these reports context. Now that COVID-19 diagnostics are available in most of the United States, media reports are surfacing about false-negative test results and the possibility of reinfection.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |